184 related articles for article (PubMed ID: 7751355)
21. Test performance comparison of inform HPV and hybrid capture 2 high-risk HPV DNA tests using the SurePath liquid-based Pap test as the collection method.
Davis-Devine S; Day SJ; Freund GG
Am J Clin Pathol; 2005 Jul; 124(1):24-30. PubMed ID: 15923167
[TBL] [Abstract][Full Text] [Related]
22. Correlation of Pap smear, cervical biopsy, and clinical follow-up with an HPV typing microarray system.
Nuovo GJ; Bartholomew D; Jung WW; Han IK; Um T; Grabarz DF; Lee DJ; McCabe RT
Diagn Mol Pathol; 2008 Jun; 17(2):107-11. PubMed ID: 18382353
[TBL] [Abstract][Full Text] [Related]
23. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus testing with a liquid-based system: feasibility and comparison with reference diagnoses.
Bergeron C; Cas F; Fagnani F; Didailler-Lambert F; Poveda JD
Acta Cytol; 2006; 50(1):16-22. PubMed ID: 16514835
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.
Tao K; Yang J; Yang H; Guo ZH; Hu YM; Tan ZY; Zhang F; Duan JL
Diagn Cytopathol; 2014 Mar; 42(3):213-7. PubMed ID: 23904341
[TBL] [Abstract][Full Text] [Related]
26. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?
Fait G; Daniel Y; Kupferminc MJ; Lessing JB; Niv J; Bar-Am A
Gynecol Oncol; 1998 Sep; 70(3):319-22. PubMed ID: 9790781
[TBL] [Abstract][Full Text] [Related]
27. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
[TBL] [Abstract][Full Text] [Related]
28. Detection of human papillomavirus on Papanicolaou-stained cervical smears using indirect in situ polymerase chain reaction hybridization.
Manavi M; Bauer M; Pischinger K; Czerwenka K
Arch Pathol Lab Med; 2001 Mar; 125(3):353-7. PubMed ID: 11231482
[TBL] [Abstract][Full Text] [Related]
29. Detection of high-risk HPV types by the hybrid capture 2 test.
Terry G; Ho L; Londesborough P; Cuzick J; Mielzynska-Lohnas I; Lorincz A
J Med Virol; 2001 Sep; 65(1):155-62. PubMed ID: 11505458
[TBL] [Abstract][Full Text] [Related]
30. Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies.
Nieh S; Chen SF; Chu TY; Lai HC; Lin YS; Fu E; Gau CH
Gynecol Oncol; 2005 Apr; 97(1):35-40. PubMed ID: 15790434
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus DNA testing by PCR-ELISA and hybrid capture II from a single cytological specimen: concordance and correlation with cytological results.
Venturoli S; Cricca M; Bonvicini F; Giosa F; Pulvirenti FR; Galli C; Musiani M; Zerbini M
J Clin Virol; 2002 Aug; 25(2):177-85. PubMed ID: 12367652
[TBL] [Abstract][Full Text] [Related]
32. Interlaboratory reliability of Hybrid Capture 2.
Castle PE; Wheeler CM; Solomon D; Schiffman M; Peyton CL;
Am J Clin Pathol; 2004 Aug; 122(2):238-45. PubMed ID: 15323141
[TBL] [Abstract][Full Text] [Related]
33. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
34. HPV testing with cytology triage for cervical cancer screening in routine practice.
Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
[TBL] [Abstract][Full Text] [Related]
35. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
36. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.
Castle PE; Schiffman M; Burk RD; Wacholder S; Hildesheim A; Herrero R; Bratti MC; Sherman ME; Lorincz A
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1394-9. PubMed ID: 12433717
[TBL] [Abstract][Full Text] [Related]
37. Improved rate of high-grade cervical intraepithelial neoplasia detection in human papillomavirus DNA hybrid capture testing.
Proca DM; Williams JD; Rofagha S; Tranovich VL; Keyhani-Rofagha S
Anal Quant Cytol Histol; 2007 Aug; 29(4):264-70. PubMed ID: 17879635
[TBL] [Abstract][Full Text] [Related]
38. Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens.
Kapala J; Jang D; Patel J; Biers K; Smieja M; Chernesky M
J Virol Methods; 2007 Jun; 142(1-2):223-5. PubMed ID: 17320978
[TBL] [Abstract][Full Text] [Related]
39. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
40. Molecular methods for a correct diagnosis of multiple HPV infections and clinical implications for vaccine.
Tinelli A; Leo G; Dell'Edera D; Storelli F; Galante MM; Guido M; Hudelist G; Malvasi A
Int J Gynecol Cancer; 2011 Apr; 21(3):545-50. PubMed ID: 21430458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
